RecruitingPhase 2NCT06451861

Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML

Studying Acute promyelocytic leukemia

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Guangdong Provincial People's Hospital
Principal Investigator: Jianyu Weng
Guangdong Provincial People Hosptial
Intervention: Chidamide(drug)
Enrollment: 240 enrolled
Eligibility: 18 years · All sexes
Timeline: 2024 – 2027

Study locations (13)

Dongguan General Hosptial, Dongguan, Guangdong, China
Foshan First People's Hospital, Foshan, Guangdong, China
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Shenzhen second people's Hospital, Shenzhen, Guangdong, China
Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China
Zhuhai General Hosptial, Zhuhai, Guangdong, China
Hainan General Hosptial, Haikou, Hainan, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06451861 on ClinicalTrials.gov

Other trials for Acute promyelocytic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute promyelocytic leukemia →

← Back to all trials